Disease Domain | Count |
---|---|
Neoplasms | 3 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Gene therapy | 10 |
Cytokines | 1 |
Biological products | 1 |
Target |
Mechanism COL7A1 gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date19 May 2023 |
Target |
Mechanism TGM1 replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CFTR gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Aug 2024 |
Sponsor / Collaborator |
Start Date17 Apr 2024 |
Sponsor / Collaborator |
Start Date15 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Beremagene geperpavec ( COL7A1 ) | Epidermolysis Bullosa Dystrophica More | Approved |
KB-105 ( TGM1 ) | Autosomal recessive ichthyosis More | Phase 2 |
KB-408 ( A1AT ) | Alpha 1-Antitrypsin Deficiency More | Phase 1 |
KB-407 ( CFTR ) | Cystic Fibrosis More | Phase 1 |
KB-707 ( IL-12 x IL-2 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |